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Abstract: Hepatocellular carcinoma (HCC) is the most common liver cancer and the third leading cause of cancer death. It has been
a major worldwide health problem with more new cases being diagnosed each year. The current available therapies for patients with
advanced HCC are extremely limited. Therefore, it is of great clinical interests to develop more effective therapies for systemic treatment
of advanced HCC. Several promising target-based drugs have been tested in a number of clinical trials. One breakthrough of these efforts
is the approved clinical use of sorafenib in patients with advanced HCC. Targeted therapies are becoming an attractive option for the treatment of advanced HCC. In this review, we summarize the most recent progress in clinical targeted treatments of advanced HCC.
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Introduction

Hepatocellular carcinoma (HCC) is the most common liver cancer and the third leading cause of cancer death. It has been one of the major global health
problems with increasing new cases coming up each
year. The major risk factors for HCC development are
hepatitis B and C viral infections, which lead to liver
cirrhosis and account for 75% of HCC cases.1,2 Other
etiologic factors include toxic chemical exposure,
alcohol abuse, and intake of aflatoxin-contaminated
food.3,4 HCC has long been a major disease in developing countries, with most cases occurring in Eastern
Asia and sub-Saharan Africa; however, there is a rising incidence in Western countries and many emerging cases are associated with hepatitis C infection,
obesity/type 2 diabetes, and nonalcoholic fatty liver
disease (NAFLD) such as nonalcoholic steatohepatitis (NASH).5,6 The worldwide incidence of HCC is
over 600,000 cases every year.7,8
Treatment of HCC is most effective in the early
stages. If diagnosed early, major treatment options
are surgery and interventional radiological therapy.
Surgical options include surgical resection, cryosurgery, radiofrequency ablation (RFA), and liver
transplantation, while interventional radiological
therapy includes hepatic artery chemoembolization,
percutaneous ethanol injection, percutaneous radio
frequency ablation, and cisplatin gel infusion. Surgery is generally believed the best treatment option
for a cure. Surgical resection is recommended for
patients who have relatively functional livers with
unifocal tumors (,5 cm). The 5-year overall survival rate can be increased up to 5-fold in wellselected patients after surgical resection.9 Liver
transplantation is another option for treatment of
early stage HCC. The most commonly used criteria for candidate selection is the Milan criteria proposed by Mazzaferro et al in 1996.10 Patients with
HCC who either have one tumor (#5 cm) or have
2 to 3 tumors (#3 cm) could be selected for liver
transplantation. The 5-year overall survival rate for
patients who have received liver transplantation is
up to 70%.11 However, the supply of donor livers
is quite limited. Therefore, selection of candidates
becomes more important to ensure the best outcome.
On the other hand, some surgeons have suggested
more inclusive parameters than the Milan criteria in
an effort to benefit more patients.
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Unfortunately, patients with HCC are usually
found to be in the advanced stages at the time of diagnosis, which severely limits these surgical options.
A widely used conventional treatment for patients with
advanced HCC is chemotherapy. However, response
rates to such treatments are poor or nonexistent given
the fact that HCC is a highly aggressive tumor that
often shows resistance to chemotherapy. Therefore,
there is an urgent clinical need to develop more effective therapies for patients with advanced HCC.
Recent discoveries in the molecular mechanisms
of HCC pathogenesis have created many opportunities for developing targeted therapies for the treatment
of advanced HCC. Some key signaling pathways
have been identified, such as epidermal growth factor receptor (EGFR) pathway, insulin-like growth
factor receptor (IGFR) pathway, vascular endothelial
growth factor (VEGF) pathway, and so on. Targeting these molecular pathways provides a potential
to generate new therapeutic approaches for the treatment of advanced HCC. One successful example is
the recently FDA approved clinical use of sorafenib,
a multikinase inhibitor, for patients with advanced
HCC.12,13 This approval unveils a new era of targeted
therapy in HCC and encourages more targeted agents
being developed and tested in the systemic treatment
of advanced HCC.
In this review, we will focus on some key targets
relevant to the signaling pathways implicated in HCC
pathogenesis and evaluate the features of such targeted therapies in clinical trials.

Hcc-Associated Molecular Pathways
and Epigenetic Regulation

The occurrence of tumor development in liver
requires genetic/epigenetic aberrations in normal
hepatocytes, which could be induced by risk factors as mentioned above. The malignant transformation of HCC, which is called hepatogenesis, is a very
complex and multistep process that may take years
to develop. The most frequent and direct risk factor
for HCC is liver cirrhosis, which is mostly developed
by hepatitis infection and chronic inflammation. The
pathogenesis of HCC eventually results in certain
genetic/epigenetic alternations, such as point mutation, chromosomal amplification/deletion, genomic
instability, gene methylation, and histone deacetylation, which ultimately lead to the dysregulation of
Clinical Medicine Insights: Oncology 2013:7
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many molecular signaling pathways. Generally, the
activation of specific oncogenes such as Ras (50%
of HCCs) and inactivation of specific tumor suppressors such as TP53 (27% of HCCs) lead to the proliferation and survival of HCC cells.14,15 Since HCC
is a highly genomic heterogeneous solid tumor, multiple oncogenic signaling pathways can be activated
simultaneously. As of yet, no single dominant signaling pathway has been found to be specifically altered
during the pathogenesis of HCC.16 It is therefore reasonable to develop therapeutic treatment for HCC by
targeting multiple signaling pathways simultaneously
using a single agent. Disrupted signaling pathways
that are associated with HCC carcinogenesis are promoting angiogenesis, enhancing growth, and inhibiting apoptosis, all of which can lead to uncontrolled
growth of tumor cells. The following pathways are
discussed due to their critical role in the course of
HCC pathogenesis.

Angiogenesis-related pathways

HCC is characterized as a hypervascular solid tumor
with a high tendency towards vascular invasion.17
The angiogenesis in HCC is essential for the tumor
growth by supplying oxygen and nutrients and is the
end result of a complex network of orchestrated action
among tumor cells, endothelial cells, and growth factors. The major mediator of the angiogenesis in HCC
is vascular endothelial growth factor (VEGF).18,19
Circulating VEGF is a key proangiogenic factor
which binds to its receptors (VEGFR1-3, mainly 2)
on endothelial cells and induces the dimerization and
autophosphorylation of the receptor, which activates
the downstream signal pathway eventually leading to
angiogenesis (Fig. 1).20 Elevated expression level of
VEGF has been found in most HCC, which is associated with poorer prognosis and decreased survival.21
Apart from VEGF, other growth factors including
the platelet-derived growth factor (PDGF), fibroblast
growth factor (FGF), and angiopoietin have been
shown to make a significant contribution to the angiogenesis in HCC.22 These growth factors thus appear
to be attractive antiangiogenesis candidates for targeted therapies.

Growth-related pathways

In addition to increased angiogenesis, dysregulation
of signaling pathways associated with cell growth
Clinical Medicine Insights: Oncology 2013:7

has also been shown to be critical in the development
of HCC (Fig. 1). Molecular aberrations of growth
pathways are directly involved in cell proliferation and the pathogenesis of HCC regarding tumor
growth, invasion, and metastasis. Some key signaling
pathways are the hepatocyte growth factor receptor
pathway (HGFR), epidermal growth factor receptor
(EGFR) pathway, insulin-like growth factor 1 receptor (IGF-1R) pathway, and PI3K/Akt/mTOR pathway.
Other pathways such as the Wnt-β catenin pathway
and the hedgehog pathway are implicated in HCC,
but the therapies targeting these pathways are only in
their early stages.

Hgf/c-Met pathway

HGF is secreted by stellate cells and is an important growth factor for liver regeneration and injury
repair.23 Its receptor is c-Met, a typical receptor
tyrosine kinase (RTK). Numerous studies have shown
that the HGF/c-Met signaling pathway is required for
normal mammalian development and is involved in
diverse cellular responses such as cell proliferation,
survival, and differentiation depending on the particular cell type and the microenvironment. Under
physiological conditions, the HGF/c-Met pathway
does not contribute significantly to the liver homeostasis; however, in circumstances of liver removal or
injury, the pathway is heavily activated as an important mediator in the liver regeneration processes.24
Deregulation and activation of c-Met may result in
unregulated cell growth and differentiation, thus contributing to malignant transformation. Like many
other RTK pathways, HGF/c-Met pathway is activated by the binding of HGF to its receptor c-MET,
which results in the receptor autophosphorylation
and the activation of the downstream intracellular
signaling pathways including the PI3K and mitogenactivated protein kinase (MAPK) pathways. c-Met
overexpression or enhanced activation relative to normal tissues has been noted in many human cancers. In
HCC, about 20% to 48% of samples from surgical
specimens showed elevated levels of c-Met, which is
associated with poor outcome in patients.25 Although
overexpression of c-Met has been found to correlate
with the increased malignancy of human HCC, there
is still lack of understanding regarding the big picture
of the exact role of this pathway in the pathogenesis
of HCC.
89
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Figure 1. Diagram of signaling pathways stimulated by ligand binding to the tyrosine kinase receptor.

EGFR pathway

EGFR, also called ErbB1 and Her1, is a member of
an RTK family of 4 related receptors, which includes
ErbB2/Her2/Neu, ErbB3/Her3, and ErbB4/Her4.26
Every member of this family has some identified
ligands except ErbB2/Her2/Neu. The most common ligand for EGFR is epidermal growth factor
(EGF), but EGFR also binds to other ligands such
as transforming growth factor α (TGF-α), amphiregulin, and β-cellulin.27 Upon binding with its
ligands, EGFR undergoes receptor homodimerization or heterodimerization with ErbB2 or ErbB3,
resulting in receptor tyrosine kinase activation and
autophosphorylation. The main downstream signaling pathways include the PI3K/Akt/mTOR pathway,
the Ras/Raf/MEK/ERK1/2-MAPK pathways, and
the signal transducer and activator of transcription
pathways (STAT 3 and 5). Activation of these pathways stimulates cellular division, survival, and apoptosis, and any alteration in these pathways aids tumor
growth and progression.28
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IGF-1R pathway

IGF-1R basically has two ligands: IGF-1 and IGF-2.
Binding of these ligands to a cysteine-rich domain
in the extracellular α subunit of IGF-1R triggers
self-dimerization and autophosphorylation of three
tyrosines in the activation loop of the tyrosine kinase
domain in the cytoplasmic portion of the β subunit,
which results in amplification of tyrosine kinase
activity and further autophosphorylation of additional tyrosine residues.29 These phosphotyrosine
containing motifs are binding sites for adaptor and
effector molecules in receptor signaling pathways.
Binding of the adaptor protein Shc and the docking
protein IRS-1 to IGF-1R activates the MAPK and
PI3/Akt/mTOR signaling pathways, respectively.
Genetic studies have demonstrated that mice deficient in IGF-1R die during the development; mice
with only one copy of IGF-1R gene exhibit almost
half body mass reduction.30–32 IGF-1R pathway plays
a crucial role in cell proliferation, differentiation,
and apoptosis.

Clinical Medicine Insights: Oncology 2013:7
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Enhanced expression of IGF-1R and IGF-2 has been
correlated with disease implication in HCC.33–35 On the
other hand, IGF binding proteins such as IGFBP-3, which
regulate the circulating concentration of IGF and IGF
in the tumor microenvironment, are downregulated.36
Further, the expression of IGF-2R, a receptor with a
relative short intracellular tail, which functions to clear
IGF-2 from cell surface to attenuate the IGF-1R signaling, is also downregulated in some HCCs.37
IGF-1R has long been a target for the treatment of
various tumors due to its overexpression on cell surface. Recent evidence shows that IGF-1R undergoes
nuclear translocation in cancer cells and autoregulates
its gene expression.38–40 We have further found that
gefitinib resistant HCC cells have an increased level of
the IGF-1R nuclear translocation.41 The biological role
of this nuclear IGF-1R in cancer cells remains unclear;
thus, nuclear IGF-1R will merit attention when designing future IGF-1R targeted therapies for HCC.

PI3K/Akt/mTOR pathway

The PI3K/Akt/mTOR pathway can be activated by
many RTK as described above and plays an essential
role in the cell survival, growth, and proliferation.42
Phosphatidylinositol 3 kinase (PI3K) has two subunits:
one subunit p85 as the adaptor and another subunit
p110 as the kinase. When associated with cytoplasmic tails of some relevant RTKs, PI3K phosphorates
phosphatidylinositol 3,4,5-triphosphate (PIP3) to
generate phosphatidylinositol 4,5-biphosphate (PIP2)
and activates Akt (also known as protein kinase B,
PKB) through phosphoinositide-dependent kinase
(PDK). The PI3K pathway can be suppressed via
dephosphorylation of PIP3 by phospharase and tensin
homologue (PTEN).43
The major mediator and regulator of this pathway is mammalian target of rapamycin (mTOR)
(Fig. 1). Once activated by PI3K, mTOR promotes
cell growth and proliferation by stimulating protein
synthesis through phosphorylation of 4E-BPs and the
S6 kinases. In addition to receiving signals from Akt,
mTOR can be directly activated by the cell’s environmental growth factors and nutrients.44 When the cell
needs additional resources, mTOR can increase nutrient uptake and promote angiogenesis. Further, mTOR
can increase the activity of Akt and thus enhance the
effect of this signaling pathway.45
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The signaling pathway that includes mTOR is
highly active in many cancer cells, including HCC.46,47
Abnormal association of PI3K to RTK or loss of function of PTEN leads to uncontrolled activation of this
pathway and causes carcinogenesis. Actually, activation of the PI3K/Akt/mTOR pathway is associated
with poor prognosis in many cancers and is linked to
resistance to many types of therapy.

Other emerging pathways

Apart from the above described signaling pathways
that are under active clinical trials for targeted therapies in HCC, there are an increasing number of other
signaling pathways that are found to be involved in
the pathogenesis of HCC. These pathways include
the Notch signaling pathway,48 the hedgehog signaling pathway,49 the transforming growth factor β
(TGF-β) signaling pathway,50,51 and the Wnt-β-catenin
pathway.52,53 Although these pathways play an important role in HCC, drugs targeting these pathways are
in early stages, and further basic and clinical studies
are needed before relevant clinical targeted therapies
can be developed.

Epigenetic regulation and microRNA

Despite deregulation of various signaling pathways
through classic genetic mutations, which either activate
oncogenes or inhibit tumor suppressor genes, cancer
development can be triggered by epigenetic mechanisms
that alter gene expression through DNA modification
without changing DNA sequences. Generally, there are
3 types of epigenetic mechanisms: gene methylation/
demethylation, histone acetylation/deacetylation, and
noncoding RNAs such as microRNAs (Fig. 2).
Gene methylation can occur in the promoter region,
rich with CpG islands. In cancer cells, tumor suppressor genes are usually silenced due to the hypermethylation of their promoter regions. Methylated promoter
region inhibits the binding of critical transcriptional
factors to the gene thus block the transcription. On
the other hand, some genes such as those involved in
tumor invasion and metastasis that are supposed to be
silent under normal physiological condition are activated in cancer cells, resulting in cancer progression.
DNA methylation has been found to have a close
connection with chromatin configuration.54,55 While
unmethylated DNA is usually associated with loose
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Figure 2. Mechanisms of epigenetic regulation in cancer gene expression.
Abbreviations: HAT, histone acetyltransferase; HDAC, histone deacetylase; miRNA, microRNA; DNMT, mammalian DNA methyltransferase.

chromatin configuration that is active for gene
transcription, methylated DNA is associated with
tight chromatin configuration that is inactive for gene
transcription. The state of chromatin configuration is
regulated by histone acetyltransferases (HATs), which
add acetyl groups to histone H3 and H4 tails, and histone deacetylases (HDACs), which remove acetyl
groups from the tails. Methylated DNA can recruit
HDACs to condense chromatin structure.
microRNAs (miRNAs) are a group of noncoding
small molecules with 18 to 23 nucleotides in length.
miRNAs are post-transcriptional gene regulators that
play crucial roles in almost every normal cellular
process. Alteration of miRNA levels can cause the
activation of oncogenes or the inhibition of tumor
suppressor genes, leading to cellular transformation
and cancer development. In most cases of cancer,
miRNAs are usually found to be downregulated.56
Recent evidence demonstrated that miRNAs can be
regulated by DNA methylation.57,58
Since aberration of epigenetic regulation is closely
associated with tumor formation, key enzymes
involved in these mechanisms such as HATs and
HDACs have becoming attractive targets of therapeutic treatment for various cancers.59,60

Mechanism of Action, Safety, and
Efficacy of Targeted Therapies in HCC

Agents that specifically disrupt targets in HCC associated molecular pathways are designed and tested
to suppress the development of liver cancer. There
are basically two types of these agents for advanced
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HCC systemic therapy: small molecule kinase inhibitors and monoclonal antibodies. Some targeted
therapies based on these agents are summarized in
Figures 2 and 3. Based on the HCC relevant signaling
pathways as described above, agents that disrupt these
pathways are reviewed and discussed in regards to the
molecular action, efficacy, safety, and metabolism.

Anti-VEGFR pathway

Sorafenib
Sorafenib (Nexavar/Bay43-9006, Bayer Pharmaceuticals Corporation, Leverkusen, Germany) is a multitargeted small molecule that inhibits the activity
of VEGFR, PDGFR, FGF as well as RAF to block
tumor proliferation and angiogenesis (Fig. 3A and B).
Sorafenib has demonstrated safety and efficacy against
a wide variety of cancers in numerous preclinical and
clinical studies.61
The pharmacokinetic characteristics of sorafenib
regarding absorption, distribution, metabolism, and
excretion have been evaluated. The peak plasma
level of sorafenib occurs around 3 hours after dosing;
however, there is no linear relationship between dosing and exposure. The bioavailability of sorafenib is
reduced when taken with food.62–64 Since sorafenib is
highly protein bound, it is estimated that there is a
large volume of distribution. Metabolism of sorafenib
is about 50%, and this drug is mainly eliminated
through the liver.63
Sorafenib established itself as an effective drug
for the treatment of advanced HCC in recent clinical trials.64–66 In two recent, large, randomized, douClinical Medicine Insights: Oncology 2013:7
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Figure 3. Molecular action of targeted agents in tyrosine kinase receptors and the corresponding signaling pathways. (A) Agents against tyrosine kinase
receptors or ligands. (B) Agents against targets in signaling pathways.

ble-blinded phase III trials, sorafenib improved the
overall survival (OS).67,68 In one trial, 602 Caucasian
patients with advanced HCC were recruited and
evaluated between sorafenib (299 patients) and placebo (303 patients). The median OS in the sorafenib
treated group was 10.7 months compared with
Clinical Medicine Insights: Oncology 2013:7

7.9 months in the placebo group. Clearly, sorafenib
increased OS out of placebo by total 44%. The hazard
ratio for sorafenib/placebo was 0.69 based on 321
deaths. Sorafenib decreased the relative risk of death
by 31%.67 In another similar trial, 226 Asian-Pacific
patients with advanced HCC (mostly developed from
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hepatitis B infection) were recruited and evaluated
between sorafenib (150 patients) and placebo
(76 patients). The median OS in the sorafenib treated
group was 6.5 months compared with 4.2 months in
the placebo group.68 Although tolerance to sorafenib
was found generally good in these two studies, there
were treatment-related adverse events. The most
frequently occurring events were diarrhea, fatigue,
weight loss, and hand-foot skin reaction.
So far, sorafenib is the only drug shown to improve
the overall survival in patients with advanced HCC
and was approved for clinical use by the US Food and
Drug Administration (FDA) in 2007.12 Other countries such as European countries and China have also
approved sorafenib for advanced HCC treatment.
Sorafenib has thus become the standard of care for
patients with advanced HCC.
More clinical trials are being tested to evaluate the
use of sorafenib in combination with other targeted
agents and conventional treatments such as chemotherapy. A finished randomized phase II clinical trial
reported an overall survival rate of 13.7 months in
patients treated with the combination of sorafenib
and doxorubicin compared with 6.5 months in
patients treated with doxorubicin alone.69 Some
other agents being tested in combination with
sorafenib are AVE1642 (NCT00791544), erlotinib
(NCT00901901), linsitinib (NCT01334710), cixutumab (NCT01008566 and NCT00906373), and temsirolimus (NCT01008917 and NCT01335074).
Sunitinib
Sunitinib (Sutent/SU11248, Pfizer Inc., New York,
USA) is another oral multikinase inhibitor like
sorafenib that mainly targets VEGFRs and PDGFRs
(Fig. 3A). This drug is well studied and has been
approved for the treatment of renal cell carcinoma
and gastrointestinal stromal tumors that are refractory
to imatinib.70
The absorption of sunitinib peaks within 6 to
12 hours after dosing. Taking the drug with food
or not has a marginal effect on the exposure.71 Like
sorafenib, sunitinib is highly protein bound and has a
large volume of distribution. Sunitinib is metabolized
by CYP3A4 and is excreted mainly via feces.72
While early clinical trials in patients with advanced
HCC showed that this drug has encouraging results on
efficacy and tolerance,73,74 the most recent phase III
94

SUN 1170 clinical trial showed that use of sunitinib
increased serious drug-related adverse events. This
trial was subsequently discontinued. Thus, sunitinib
is no longer tested for the treatment of advanced
HCC.75
Vandetanib
Vandetanib (Zactima/ZD6474, AstraZeneca, Wilmington,
USA) is an oral tyrosine kinase inhibitor of VEGFR
(Fig. 3A). This compound also inhibits the activities of EGFR and the rearranged during transfection
(RET) tyrosine kinase receptor. Vandetanib has been
approved by FDA for the treatment of medullary thyroid cancer. In the treatment of advanced HCC, vandetanib was shown to exert inhibitory effects on cell
proliferation and migration in preclinical models.76 A
phase II, placebo-controlled clinical trial (69 patients)
showed limited efficacy and safety in patients with
advanced HCC. However, it seems further evaluation with a larger population of patients is needed to
confirm the benefit of vandetanib on HCC. The most
common adverse effect profile of vandetanib is diarrhea and rash.77
Brivanib
Brivanib (BMS-582664, Bristol-Meyers Squibb,
New York, USA) is an oral selective inhibitor of
VEGFR and EGFR (Fig. 3A). Brivanib demonstrated
significant antitumor activity in HCC xenograft models by decreasing tumor microvessel density and
increasing apoptosis of tumor cells.78 Brivanib has
been evaluated as a first line and a second line agent
in advanced HCC treatments. As a first line therapy in a phase II clinical trial, brivanib achieved a
median 10 months OS.79 In a second line therapy after
prior treatment with sorafenib, the median OS was
9.8 months. Major drug-related adverse events were
fatigue, nausea, loss of appetite, diarrhea, and hypertension.80 More clinical trials are currently underway
to further evaluate the antitumor activity in patients
with advanced HCC.
Bevacizumab
Bevacizumab (Avastin, Genetech, San Francisco,
USA and Roche, Basel, Switzerland) is a recombinant humanized monoclonal antibody neutralizing the
biological activity of VEGF (Fig. 3A). Bevacizumab
has been approved for the treatments of colorectal,
Clinical Medicine Insights: Oncology 2013:7
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non-small-cell lung, and breast cancers. It is the first
antibody against VEGF to be tested in HCC and has
been evaluated as both single agent and in combination with other drugs.
A phase II trial including a total of 46 patients with
locally advanced HCC showed promising results:
13% of patients showed partial responses and 65%
of patients obtained disease stabilization for up to
6 months.81 However, since some patients with severe
diseases were excluded from this trial, the clinical
benefit obtained from bevacizumab treatment seems
only suitable to well-selected patients. Benefit for a
broad range of patients shown in a large scale study is
needed to further endorse the activity of bevacizumab
in advanced HCC. The major drug-related adverse
event was severe hemorrhagic complications (11%);
other drug-related adverse events were arterial thrombosis (6%) and hypertension (15%).
The combination use of bevacizumab with other
chemotherapy agents such as gemcitabine, capecitabine, and erlotinib has been evaluated in some phase
II trials and showed moderate clinical benefit with
reasonable safety.82–84
Ramucirumab
Ramucirumab (IMC-1121B, ImClone Systems Inc.,
New York, USA) is a fully human immunoglobulin
G1 monoclonal antibody specifically developed to
bind to the extracellular VEGF-binding domain of
VEGFR-2 and block the activation of its receptor
tyrosine kinase and the downstream signaling pathways (Fig. 3A).
Ramucirumab was tested in various solid tumors
including HCC in a phase I trial and showed objective
antitumor activity with reasonable safety. The most
frequently reported serious events included hypertension (13.5%), abdominal pain (10.8%), and anorexia,
vomiting, headache, and proteinuria (each in 5.4% of
patients).85
Preliminary data from a phase II study of 42 patients
with advanced HCC showed that, as a single agent
in a first-line monotherapy, ramucirumab achieved a
disease control rate of 50% and a median progression-free survival (PFS) of 4.3 months.86 Based on
this positive study, a phase III clinical trial in HCC
comparing ramucirumab with placebo for the secondline treatment after sorafenib is underway (Table 1,
NCT01140347).
Clinical Medicine Insights: Oncology 2013:7

Anti-HGF/c-Met pathway

Foretinib
Foretinib (XL880/GSK1363089, GlaxoSmithKline,
Brentford, United Kingdom) is an oral selective small
molecule inhibitor of c-Met and VEGFR-2 (Fig. 3A).
Since overexpression of c-Met in HCC correlates
well with the progress of this disease,87 it is generally
anticipated that targeting c-Met using foretinib could
produce clinical benefit in patients with advanced
HCC. Evidence supporting this notion is the recent
observations that cells lacking c-Met expression do
not respond well to c-Met inhibitor and that foretinib
exhibits inhibitory effects on angiogenesis, cell proliferation, and tumor metastasis in preclinical HCC
models.88,89
A phase I/II study in patients with advanced HCC
is being tested for safety and tolerance of foretinib
(NCT00920192).
Tivantinib
Tivantinib (ARQ197, ArQule, Inc., Woburn, USA)
is the first in class orally available selective inhibitor
of c-Met (Fig. 3A). This is also a novel, non-ATPcompetitive c-Met inhibitor, the most advanced agent
in a new class of trans-3,4-bisubstituted pyrrolidine2,5-diones.90
Results from a phase Ib clinical trial of 21 patients
with advanced HCC showed antitumor activity with
progression-free rates at 2 and 4 months of 59.7% and
39.8%, respectively. The study also found a manageable toxicity of tivantinib with anemia (43%), asthenia
(43%), neutropenia (38%), leukopenia (33%), diarrhea (29%), anorexia (29%), and fatigue (24%).91
On the basis of results from the phase Ib study, a
global, randomized, double-blind, placebo-controlled,
phase II clinical trial in patients with unresectable
HCC is currently enrolling patients (NCT00988741).

Anti-EGFR pathway

Gefitinib
Gefitinib (Iressa/ZD1839, AstraZeneca) is the first
small molecular inhibitor of EGFR tyrosine kinase
(Fig. 3A). Gefitinib inhibits EGFR tyrosine kinase
activity by binding to the ATP-binding site of the
receptor and blocking the Ras signaling pathway.
Gefitinib is developed to treat cancers in which
EGFR is overexpressed, such as lung cancer and
breast cancer. Although demonstrated the ability
95
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Table 1. Molecular targeted agents used for clinical trials in HCC.*
Agent

Classification

Target

Stage

Sorafenib
Vandetanib

Small molecule compound
Small molecule compound

VEGFR, PDGFR, RAF
VEGFR, EGFR

Approved
Phase I/II

Brivanib

Small molecule compound

VEGFR, FGFR

Phase III

Sunitinib
Bevacizumab
Ramucirumab

Small molecule compound
Monoclonal antibody
Monoclonal antibody

VEGFR, PDGFR
VEGF
VEGFR

Phase III
Phase II
Phase II/III

Foretinib
Tivantinib
(ARQ197)
Gefitinib

Small molecule compound
Small molecule compound

c-Met, VEGFR
c-Met

Phase I/II
Phase I/II

Small molecule compound

EGFR

Phase II

Erlotinib

Small molecule compound

EGFR

Phase I/II

Lapatinib

Small molecule compound

EGFR

Phase II

Cetuximab
Linsitinib
(OSI-906)
AVE1642
Cixutumumab
Sirolimus
Everolimus
Selumetinib
(AZD6244)
Belinostat

Monoclonal antibody
Small molecule compound

EGFR
IGF-1R

Phase II
Phase II

Monoclonal antibody
Monoclonal antibody
Small molecule compound
Small molecule compound
Small molecule compound

IGF-1R
IGF-1R
mTOR
mTOR
MEK

Phase I/II
Phase II
Phase II
Phase I/II
Phase I/II

Small molecule compound

HDAC

Phase II

Trial identifier
NCT00496509
NCT00508001
NCT00858871
NCT00825955
NCT00699374
NCT00162669
NCT00627042
NCT01140347
NCT00920192
NCT00802555
NCT00988741
NCT00071994
NCT00282100
NCT00047346
NCT00047333
NCT00107536
NCT00101036
NCT00142428
NCT01101906
NCT00791544
NCT00639509
NCT01374750
NCT00390195
NCT00550719
NCT00604721
NCT00321594

Note: *Information gathered from ClinicalTrials.gov and references.98,123,124

to prevent HCC development in a murine model,92
when applied to HCC in a phase II clinical trial with
31 patients enrolled, gefitinib induced a median OS
of 6.5 months. Since the results did not meet the criterion for the second stage of the study, the authors
concluded that this drug alone did not exhibit significant antitumor activity in patients with advanced
HCC.93
Our recent study showed that gefitinib resistance in
HCC cells was associated with IGF-1R nuclear translocation and accumulation.41 It seems that nuclear IGF1R may play an important role in gefitinib resistance
in HCC. Inhibiting IGF-1R expression using a specific
miRNA may help improve the efficacy of gefitinib.
Erlotinib
Erlotinib (Tarceva/OSI774, Genetech Inc. and
Roche) is an oral specific inhibitor of EGFR
tyrosine kinase (Fig. 3A). Erlotinib shares the common chemical backbone structure with gefitinib.
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The peak plasma levels occur 4 hours after dosing.
It is not recommended to take erlotinib with food.
Like gefitinib, erlotinib is highly protein bound and
has an extensive distribution in tissues. It is predominantly metabolized by CYP3A4 and CYP3A5,
and 91% of the dose of 100 mg was recovered over
11 days.94,95
As a more potent small molecule compound than
gefitinib, erlotinib showed antitumor activity in a
variety of solid tumors including advanced lung
cancer and pancreatic cancer. Two phase II clinical
studies using erlotinib as the first line therapy were
conducted in patients with advanced HCC. The
first trial (38 patients enrolled) reported a median
OS of 13 months and the PFS at 6 months in 32%
of patients.96 The second trial (40 patients enrolled)
reported a median OS of 10.75 months and the PFS
at 4 months in 43% patients.97 More clinical trials are
ongoing to evaluate the combination of erlotinib with
sorafenib and other agents.98
Clinical Medicine Insights: Oncology 2013:7

Review of targeted therapies for advanced HCC

Some of the major side effects found in a combined
trial with bevacizumab were fatigue (20%), hypertension (15%), and gastrointestinal bleeding (12.5%).99
Lapatinib
Lapatinib (Tyverb/GW572016, GlaxoSmithKline) is
a dual tyrosine kinase inhibitor that blocks EGFR and
HER2/NEU signaling pathways (Fig. 3A). Lapatinib
is an orally active small molecule originally designed
for the treatment of breast cancer with elevated
expression of EGFR and HER2/NEU.
The pharmacokinetics of lapatinib were reported
in some studies. The peak plasma concentration could
be reached within 3 to 4 hours after dosing, and food
does not significantly reduce its half life.100 Lapatinib
is highly protein bound, and the volume of distribution
is large. CYP3A4 is the main metabolizing enzyme of
lapatinib. Excretion of lapatinib is primarily through
the liver.101
Although HCC cells usually do not express a
high level of EGFR and HER2/NEU, lapatinib was
evaluated in two separate phase II clinical trials.
In one study, 26 patients with advanced HCC were
included. The median OS and PFS were 12.6 months
and 1.9 months, respectively. Ten patients (40% of
total enrolled) showed stable disease, and 6 patients
(23% of total enrolled) had stable disease lasting
more than 120 days. The most common drug-related
adverse events observed in this trial were diarrhea
(73%), nausea (54%), and rash (42%).102 In another
study, a total of 40 patients with advanced HCC were
tested. The median OS and PFS were 6.2 months and
2.3 months, respectively. Although tolerance to this
drug was high, only 5% of patients showed objective
response. Results from this trial indicated that therapy
with lapatinib in HCC did not meet the target efficacy
rate.103
Cetuximab
Cetuximab (Erbitux/IMC-C225, Bristol-Meyers
Squibb, and Merck Serono, Geneva, Switzerland) is a
chimeric monoclonal antibody neutralizing the extracellular domain of EGFR from the binding of EGF
(Fig. 3A). This antibody drug is given by intravenous
infusion and has been used in treatment of metastatic
colorectal cancer and head and neck cancer.103,104
Evaluation of cetuximab as a single agent treatment in advanced HCC was tested in two phase II
Clinical Medicine Insights: Oncology 2013:7

clinical trials. The median OS and PFS observed in
the first trial with 30 patients enrolled were 9.6 months
and 1.4 months, respectively. Although stable disease
was found in 17% patients, no clinical responses were
observed in this study.105 In a similar designed second study, 27 patients within the total of 32 enrolled
were evaluated for efficacy. Again, there were no
clinical responses. The median PFS was 1.8 months,
and the stable disease was observed in 44.4% patients
for 8 weeks.106 In combination with gemcitabine and
oxaliplatin (GEMOX), cetuximab was evaluated in
another phase II clinical trial. The clinical response
rate was 23%. However, since no data are available
for cetuximab as a single agent and GEMOX regimen
showed antitumor activity before, the exact contribution of cetuximab in this trial remains unknown.107

Anti-IGF-1R pathway

Linsitinib
Linsitinib (OSI-906, OSI Phamaceuticals, Farmingdale, USA) is a novel dual tyrosine kinase inhibitor
of IGF-1R and insulin receptor (IR) (Fig. 3A).
Linsitinib is a small molecular compound that specifically binds to the intracellular domain of IGF-1R and
IR and blocks the autophosphorylation of the receptors and the downstream signaling pathways.108
A phase II clinical trial was initiated to evaluate its efficacy and safety in patients with advanced
HCC as a second line of therapy for HCC refractory
to a first line sorafenib therapy (NCT01101906).
Unfortunately, the company recently announced the
termination of this trial.
AVE1642
AVE1642 (Sanofi-Aventis, Paris, France) is a humanized monoclonal antibody that specifically blocks
IGF-1R signaling by binding to the extracellular
domain (Fig. 3A).
A phase I clinical trial reported that AVE1642 can
be safely combined with active doses of sorafenib in
patients with advanced HCC. This combination did
not interfere the pharmacokinetics of either AVE1642
or sorafenib at the concentrations tested and achieved
a mean PFS of 13.3 weeks in most patients.109
Cixutumumab
Cixutumumab (IMC-A12, ImClone System Inc.)
is also a humanized monoclonal antibody that
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specifically neutralizes the extracellular IGF-1 binding domain of IGF-1R and inactivates the subsequent
signaling pathways (Fig. 3A).
Preclinical data showed that cixutumumab blocks
proliferation, induces apoptosis, and delays tumor
growth both in vitro and in vivo.110 A recent phase II
clinical trial in 22 patients with advanced HCC showed
that a median OS was 8 months, and 7 patients (29%
of total) had stable disease for at least 4 months.
However, the study concluded that cixutumumab
had no antitumor activity as a single agent in HCC,
although an initial phase I study reported partial
activity.111,112
Recent research progress may explain the lack of
activities of antibody drugs targeting IGF-1R in clinical trials. IGF-1R has been found to migrate and accumulate in cancer cell nuclei, and drug-resistant cancer
cells have increased levels of nuclear IGF-1R.38–41
It seems that direct inhibition of the expression of
IGF-1R in cancer cells might improve the antitumor
activity and cancer drug sensitivity. Nuclear IGF-1R
should be considered in the future design of IGF-1Rbased targeted therapies.

Anti-mTOR pathway

Sirolimus and everolimus
Sirolimus and everolimus (RAD001, Novartis, Basel,
Switzerland) are analogues of rapamycin and selective
inhibitors of mTOR kinase (Fig. 3B). Since mTOR
plays a pivotal role in signal transduction of many
receptor tyrosine kinase induced signaling pathways,
inhibiting mTOR should have the antitumor activity
for a broad range of cancer stimuli.
Experimental studies using this rapamycin and
its analogue everolimus (RAD001) in HCC cells
showed significant effects in reducing tumor cell
growth and improving cell survival.113,114 One recent
phase I/II study in 28 patients with advanced HCC
showed everolimus had clinical activity with a
median OS of 8.4 months.115 Promising results on the
efficacy in patients with advanced HCC were also
reported from two pilot clinical trials using sirolimus.
The first study, with 21 patients enrolled, showed a
median OS of 6.5 months and stable disease for at
least 3 months in 24% of patients.112 The second study,
with 14 patients enrolled, observed a complete clinical response in 7% of patients and partial response in
33% of patients. In addition, sirolimus demonstrated
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a safe profile because no major drug-related adverse
events were observed in these studies.116
Several ongoing trials are currently recruiting
patients with advanced HCC to determine the combinational effects of these drugs with sorafenib and
conventional chemotherapeutic agents.
It is worth noting that cancer drug sensitivity can
be improved in patients with certain gene mutations.
For example, a recent study, using the whole genome
sequencing technology, identified loss of function
mutations in tuberous sclerosis complex 1 (TSC1),
a regulator of mTOR pathway activation. Patients
with the TSC1 gene mutations in bladder tumors
showed an increased everolimus sensitivity and better outcomes.117

Anti-MEK/ERK pathway

Selumetinib
Selumetinib (AZD6244/ARRY-142886, AstraZeneca)
is an orally active new inhibitor that binds to MEK to
block the RAF/MEK/ERK pathway, which appears
to be the most significant signaling pathway in HCC
development (Fig. 3B).
Selumetinib showed significant antitumor activity
both in vitro with HCC cells and in vivo with xenografts.118 However, when tested in a phase II study in
19 patients with advanced HCC, selumetinib failed to
exhibit convincing antitumor activity.119 Results from
this clinical trial suggest that inhibition of RAF/MEK/
ERK pathway using selumetinib as a single agent in
the treatment of HCC is not effective.
Combinational use of selumetinib with other agents
is under active evaluation in separate clinical trials.

Anti-epigenetic regulation

Belinostat
Belinostat (PXD101, Spectrum Pharmaceuticals,
Irvine, USA) is a small compound inhibitor of HDAC
(Fig. 2). In a preclinical study with 3 HCC cell lines,
belinostat showed inhibitory effects on cell growth on
a dose-based manner and provided the basis for further clinical trials.120
In a multicenter phase I/II clinical trial, belinostat was tested in patients (18 in phase I and 42 in
phase II) with unresectable HCC and chronic liver
disease. The pharmacokinetics of belinostat demonstrated a linear relationship from 600 to 1400 mg/m2
with no significant accumulation. When used with a
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1400 mg/m2 dose in the phase II study, the stable disease rate was 45.2%. Among patients whose tumors
expressed high levels of RAD23B, 58% achieved disease stabilization compared with 14% of those with
low RAD23B expression in their tumors. Further, the
median OS and PFS obtained from this trial were 6.6
and 2.64 months, respectively.121
This clinical trial suggested that belinostat can
safely stabilize unresectable HCC. Furthermore, the
expression level of RAD23B may be eventually used
as a biomarker for belinostat clinical response and as
a helpful guide for a personalized medicine approach
for HCC treatment.122
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Targeted therapies that specifically block tumorassociated signaling pathways using either small
molecular compounds or humanized monoclonal
antibodies to inhibit angiogenesis and tumor growth
represent a new trend of promising novel treatments
of HCC. The success of sorafenib in the treatment of
patients with advanced HCC has established sorafenib
as a new standard of care for patients with advanced
HCC and encourages a number of novel agents being
tested in clinical trials. Results of pharmacokinetics,
safety, and efficacy obtained from those finished and
ongoing trials will definitely provide valuable information for the future improvement of the targeted
therapies in HCC.
While use as a single agent for the first-line therapy
may not display full benefits to patients, sorafenib is
being tested with either another targeted agent or conventional treatments such as chemotherapy and surgery
as the second-line therapy. More clinical trials are thus
needed for those emerging novel agents both as single
agents and in combination with other therapies.
The design of targeted therapies is primary based
on our understanding at the molecular level of the
relationship between signaling pathways and the
disease. Given the fact that HCC is highly heterogeneous and no dominant signaling pathway has been
found so far, more investigations are warrant in the
future to elucidate the molecular pathogenesis of this
disease and the underlying mechanisms.
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